GlassScriptPhysician profile
Kelly Merchie
NPI 1265048870
$15,144.00
in general payments reported to CMS, 2019-2025
46 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,579 · 2023: $5,166 · 2024: $3,621 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,911 · Travel and Lodging: $2,529 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,911.28 |
| Travel and Lodging | $2,528.61 |
| Education | $125.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,502.02 | 2022-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $2,037.89 | 2022-2025 | |
| Abbott Laboratories | $1,612.12 | 2024 | Infinity, Proclaim |
| Harmony Biosciences LLC | $1,135.79 | 2022-2025 | Wakix |
| Argenx US, INC. | $735.86 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $680.83 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $551.41 | 2022-2023 | Quviviq |
| Amgen INC. | $437.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $378.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $372.01 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $371.28 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $332.87 | 2022-2025 | Crexont, Rytary, Lyvispah |
| Lilly USA, LLC | $321.17 | 2022-2025 | Reyvow, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $316.50 | 2022-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $308.94 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $303.98 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $295.85 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $293.70 | 2022-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $278.74 | 2022-2024 | Ultomiris |
| Sk Life Science, INC. | $220.97 | 2023-2025 | |
| Biogen, INC. | $195.65 | 2022 | |
| Lundbeck LLC | $194.14 | 2023-2025 | Vyepti, Rexulti |
| Ucb, INC. | $186.62 | 2023-2024 | Briviact, Rystiggo |
| Pfizer INC. | $150.59 | 2023-2025 | |
| Mdd US Operations, LLC | $145.98 | 2022-2025 | Gocovri, Xadago, Apokyn |
| Axsome Therapeutics, INC. | $128.60 | 2022-2023 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $101.88 | 2024 | Zeposia |
| Kyowa Kirin, INC. | $69.56 | 2022-2023 | Nourianz |
| Mallinckrodt Hospital Products INC. | $62.01 | 2023-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $49.62 | 2023-2024 | Hyqvia |
| Neurelis, INC. | $41.99 | 2023 | Valtoco |
| Csl Behring | $37.48 | 2025 | Hizentra |
| Ge Healthcare | $36.94 | 2025 | |
| C2n Diagnostics, LLC | $27.71 | 2025 | Precivityad2 |
| Mirum Pharmaceuticals, INC. | $26.88 | 2025 | Cholbam |
| Inspire Medical Systems, INC. | $23.12 | 2023 | Inspire |
| Cala Health, INC. | $21.63 | 2023 | Cala Trio, Cala Kiq |
| Corium, LLC | $20.63 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $19.29 | 2023 | Fycompa |
| Sumitomo Pharma America, INC. | $18.95 | 2023 | Aptiom |
| Impel Pharmaceuticals INC. | $17.78 | 2023 | Trudhesa |
| Emd Serono, INC. | $16.70 | 2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $16.70 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2025 | Caplyta |
| Genzyme Corporation | $15.86 | 2023 | |
| Genentech USA, INC. | $14.21 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Merchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.